Cargando…

Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review

BACKGROUND: Infections are among the main causes of death in patients with demyelinating diseases of the central nervous system (CNSDD). Vaccines are effective methods in reducing hospitalization and death from infectious diseases, but they are challenging in patients with CNSDD because of autoimmun...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Guilherme Diogo, de Oliveira, Vítor Falcão, Mendonça, Leonardo Oliveira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academia Brasileira de Neurologia - ABNEURO 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491426/
https://www.ncbi.nlm.nih.gov/pubmed/35976311
http://dx.doi.org/10.1590/0004-282X-ANP-2022-S121
_version_ 1784793275297693696
author Silva, Guilherme Diogo
de Oliveira, Vítor Falcão
Mendonça, Leonardo Oliveira
author_facet Silva, Guilherme Diogo
de Oliveira, Vítor Falcão
Mendonça, Leonardo Oliveira
author_sort Silva, Guilherme Diogo
collection PubMed
description BACKGROUND: Infections are among the main causes of death in patients with demyelinating diseases of the central nervous system (CNSDD). Vaccines are effective methods in reducing hospitalization and death from infectious diseases, but they are challenging in patients with CNSDD because of autoimmunity and immunosuppression. OBJECTIVES: To summarize the pathophysiological rationale and main evidence for vaccine recommendations in patients with CNSDD. METHODS: Specialists with different backgrounds on the subject: a neurologist specialized in demyelinating diseases, an infectious diseases specialist and an immunologist, presented a critical narrative review of vaccination literature in patients with CNSDD, highlighting which vaccines should or should not be administered and the best time for it. RESULTS: Patients with DDSNC are at increased risk of vaccine-preventable viral and bacterial infections. Vaccines can prevent herpes zoster, hepatitis B reactivation, HPV-associated warts and tumors, viral and bacterial pneumonia, and meningitis. Live attenuated virus vaccines should not be used when the patient is on immunosuppression. Vaccines should be avoided during relapses. The greatest vaccine efficacy is given before treatment or at the end of medication. CONCLUSION: Patients with DDSNC need differentiated immunization in relation to additional vaccines, contraindicated vaccines and timing of vaccination.
format Online
Article
Text
id pubmed-9491426
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Academia Brasileira de Neurologia - ABNEURO
record_format MEDLINE/PubMed
spelling pubmed-94914262022-12-08 Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review Silva, Guilherme Diogo de Oliveira, Vítor Falcão Mendonça, Leonardo Oliveira Arq Neuropsiquiatr Inflammatory and Demyelinating Disease BACKGROUND: Infections are among the main causes of death in patients with demyelinating diseases of the central nervous system (CNSDD). Vaccines are effective methods in reducing hospitalization and death from infectious diseases, but they are challenging in patients with CNSDD because of autoimmunity and immunosuppression. OBJECTIVES: To summarize the pathophysiological rationale and main evidence for vaccine recommendations in patients with CNSDD. METHODS: Specialists with different backgrounds on the subject: a neurologist specialized in demyelinating diseases, an infectious diseases specialist and an immunologist, presented a critical narrative review of vaccination literature in patients with CNSDD, highlighting which vaccines should or should not be administered and the best time for it. RESULTS: Patients with DDSNC are at increased risk of vaccine-preventable viral and bacterial infections. Vaccines can prevent herpes zoster, hepatitis B reactivation, HPV-associated warts and tumors, viral and bacterial pneumonia, and meningitis. Live attenuated virus vaccines should not be used when the patient is on immunosuppression. Vaccines should be avoided during relapses. The greatest vaccine efficacy is given before treatment or at the end of medication. CONCLUSION: Patients with DDSNC need differentiated immunization in relation to additional vaccines, contraindicated vaccines and timing of vaccination. Academia Brasileira de Neurologia - ABNEURO 2022-08-12 /pmc/articles/PMC9491426/ /pubmed/35976311 http://dx.doi.org/10.1590/0004-282X-ANP-2022-S121 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Inflammatory and Demyelinating Disease
Silva, Guilherme Diogo
de Oliveira, Vítor Falcão
Mendonça, Leonardo Oliveira
Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review
title Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review
title_full Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review
title_fullStr Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review
title_full_unstemmed Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review
title_short Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review
title_sort challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review
topic Inflammatory and Demyelinating Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491426/
https://www.ncbi.nlm.nih.gov/pubmed/35976311
http://dx.doi.org/10.1590/0004-282X-ANP-2022-S121
work_keys_str_mv AT silvaguilhermediogo challengesandinsightsinimmunizationinpatientswithdemyelinatingdiseasesabenchtobedsideandevidencebasedreview
AT deoliveiravitorfalcao challengesandinsightsinimmunizationinpatientswithdemyelinatingdiseasesabenchtobedsideandevidencebasedreview
AT mendoncaleonardooliveira challengesandinsightsinimmunizationinpatientswithdemyelinatingdiseasesabenchtobedsideandevidencebasedreview